Screening for diabetes in general practice

Preventive Cardiology

Volumn 6, Issue 2, 2003, Pages 78-84

  Lawrence, James ^a   Robinson, Anthony ^a,b  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BATH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; EARLY DIAGNOSIS; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 0038031942     PISSN: 1520037X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1520-037X.2003.01662.x     Document Type: Review

References (60)

1. Cruikshank K. The epidemiology of diabetes mellitus. In: Pickup J, Williams G, eds. Textbook of Diabetes. Oxford, England: Blackwell Science; 1997:3.1-3.28.
2. Engelgau MM, Venkat Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care. 2000;23:1563-1580.
3. Harris MI, Modan M. Screening for non-insulin dependent diabetes mellitus. Why is there no national program? Diabetes Care. 1994;17:440-444.
4. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 1993;16:642-652.
5. American Diabetes Association. Screening for type 2 diabetes. Position statement. Diabetes Care. 2000;23:1-7.
6. Diabetes United Kingdom. Early identification of people with type 2 diabetes. Position statement. Available at: http://www.diabetes.org.uk. 2002;1-7. Accessed February 2002.
7. Diabetes Australia. Guidelines for the management of type 2 diabetes mellitus. Available at: www.diabetesaustralia.com.au/main.htm. 2000;125-246. Accessed February 2002.
8. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2:120-126.
9. Barrett-Connor E, Wingard DL. Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol. 1983;118:489-496.
10. Reckless JPD. The epidemiology of heart disease in diabetes mellitus. In: Taylor KG, ed. Diabetes and the Heart. Tunbridge Wells, UK: Castle House Publications; 1987:1-18.
11. Economic consequences of diabetes mellitus in the US in 1997. American Diabetes Association. Diabetes Care. 1998;21:296-309.
12. Vaccaro O, Ruffa G, Imperatore G, et al. Risk of diabetes in the new diagnostic category of impaired fasting glucose. A prospective analysis. Diabetes Care. 1999;22:1490-1493.
13. Charles A, Fontbonne A, Thibult N, et al. Risk factors for non-insulin dependent diabetes mellitus in white population. Paris Prospective Study. Diabetes. 1991;40:796-799.
14. Harris MI, Klein R, Welborn TA, et al. Onset of non-insulin dependent diabetes mellitus occurs at least 4-7 years before clinical diagnosis. Diabetes Care. 1992;15:815-819.
15. Diabetes United Kingdom. Audit shows 10-year delay in diagnosing type 2 diabetes. Diabetes Update. 2000;Winter:1.
16. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
17. United Kingdom Prospective Diabetes Study Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. (UKPDS 34). Lancet. 1998;352:854-865.
18. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
19. Ramsay L, Williams B, Johnston G, et al. Guidelines for management of hypertension: report of the 3rd working party of the British Hypertension Society. J Hum Hypertens. 1999;13:569-592.
20. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
21. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care. 1997;20:1772-1773.
22. Hulley SB, Grady D, Browner WS. Statins: underused by those who would benefit, but caution is needed for young people at low risk of cardiovascular disease. BMJ. 2000;321:971-972.
23. Costa A, Rios M, Fernandez M, et al. The 1997 American Diabetes Association diabetes diagnostic categories: impact on employees' annual medical examination. Diabetes Med. 1999;16:528-529.
24. Modan M, Harris MI. Fasting plasma glucose in screening for non-insulin dependent diabetes mellitus in the United States and Israel. Diabetes Care. 1994;17:436-439.
25. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia. 1999;42:647-654.
26. Blunt BA, Barrett-Connor E, Wingard DL. Evaluation of fasting plasma glucose as screening test for non-insulin dependent diabetes mellitus in older adults. Rancho Bernardo study. Diabetes Care. 1991;14:989-993.
27. Davies MJ, Williams DRR, Metcalfe J, et al. Community screening for non-insulin dependent diabetes mellitus: self-testing for postprandial glycosuria. QJM. 1993;86:677-684.
28. Davies M, Alban-Davies H, Cook C, et al. Self testing for diabetes mellitus. BMJ. 1991;303:696-698.
29. Davidson MB, Schriger DL, Peters AL, et al. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 1999;281:1203-1210.
30. Herman WH, Smith PJ, Thompson TJ, et al. A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes. Diabetes Care. 1995;18:382-387.
31. Newman WP, Nelson R, Scheer K. Community screening for diabetes. Low detection rate in a low-risk population. Diabetes Care. 1994;17:363-365.
32. Burden ML, Burden AC. The ADA screening questionnaire for diabetes. Is it worthwhile in the UK? Diabetes Care. 1994;17:97.
33. Knudson PE, Turner KJ, Sedore A, et al. Utility of the American Diabetes Association risk test in a community screening program. Diabetes Care. 1998;21:1029-1031.
34. Herman WH, Dasbach EJ, Songer TJ, et al. The cost-effectiveness of intensive therapy for diabetes mellitus. Endocrin Metab Clin North Am. 1997;26:679-695.
35. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA. 1998;280:1757-1763.
36. Graham JD, Corso PS, Morris JM, et al. Evaluating the costeffectiveness of clinical and public health measures. Annu Rev Public Health. 1998;19:125-152.
37. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. BMJ. 2001;322:986-988.
38. Cowie CC, Harris MI, Eberhardt MS. Frequency and determinants of screening for diabetes in the US. Diabetes Care. 1994;17:1158-1163.
39. Lawrence JM, Bennett P, Young A, et al. Screening for diabetes in general practice: cross-sectional population study. BMJ. 2001;323:548-551.
40. Resnick HE, Harris MI, Brock DB, et al. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular risk profiles. Results from the 3rd National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2000;23:176-180.
41. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care. 1998;21:1236-1239.
42. The DECODE Study Group. Glucose tolerance and mortal ity: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617-621.
43. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
44. The Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
45. Balkau B, Shipley MJ, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Heart Study. Diabetes Care. 1998;21:360-367.
46. Bjornholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care. 1999;22:45-49.
47. Lowe LP, Liu K, Greenland P, et al. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care. 1997;20:163-169.
48. Coutino M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-240.
49. Forrest RD, Jackson CA, Yudkin JS. The glycohemoglobin assay as a screening test for diabetes mellitus: The Islington Diabetes Survey. Diabetes Med. 1987;4:254-259.
50. Andersson DK, Lundblad E, Svardsudd K. A model for early diagnosis of type 2 diabetes mellitus in primary health care. Diabetes Med. 1993;10:167-173.
51. Hanson RL, Nelson RG, McCance DR, et al. Comparison of screening tests for non-insulin dependent diabetes mellitus. Arch Intern Med. 1993;153:213-240.
52. Ko GT, Chan JC, Yeung VT, et al. Combined use of a fasting plasma glucose concentration and HbAlc or fructosamine predicts the likelihood of having diabetes in high-risk subjects. Diabetes Care. 1998;21:1221-1225.
53. Haffner SM, Rosenthal M, Hazuda HP, et al. Evaluation of three potential screening tests for diabetes mellitus in a biethnic population. Diabetes Care. 1984;7:347-353.
54. Swai A, Harrison K, Chuwa LM, et al. Screening for diabetes: does measurement of serum fructosamine help? Diabetes Med. 1988;5:648-652.
55. Lee CH, Fook-Chong S. Evaluation of fasting plasma glucose as a screening test for diabetes mellitus in Singaporean adults. Diabetes Med. 1997;14:119-122.
56. Wiener K. Fasting plasma glucose as a screening test for diabetes mellitus. Diabetes Med. 1997;14:711-712.
57. Chang CJ, Wu JS, Lu FH, et al. Fasting plasma glucose in screening for diabetes in the Taiwanese population. Diabetes Care. 1998;21:1856-1860.
58. Borthiery AL, Malberi DA, Franco LJ. The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT. Diabetes Care. 1994;17: 1269-1272.
59. Ferrell RE, Hanis CL, Aguilar L, et al. Glycosylated hemoglobin determination from capillary blood samples. Utility in an epidemiologic survey of diabetes. Am J Epidemiol. 1984;119:159-166.
60. Engelgau MM, Thompson TJ, Smith PJ, et al. Screening for diabetes mellitus in adults. The utility of random capillary blood glucose measurements. Diabetes Care. 1995;18:463-466.